Company profile: Penumbra
1.1 - Company Overview
Company description
- Provider of neurovascular and peripheral vascular devices, including: Lightning Flash mechanical thrombectomy for pulmonary embolism and venous thrombus; Penumbra System for mechanical thrombectomy in acute ischemic stroke due to intracranial large vessel occlusions; Artemis Neuro Evacuation Device for controlled aspiration; Indigo System for arterial/venous clot removal; PC400 coils for aneurysms and malformations; and POD400/PAC400 for predictable vessel occlusion.
Products and services
- Penumbra System: A custom-engineered mechanical thrombectomy system targeting acute ischemic stroke due to intracranial large vessel occlusions, built to perform clot removal
- Indigo System: An industrial-grade thrombectomy system engineered to remove clots from arteries and veins in the peripheral vasculature, including treatment of pulmonary embolism
- Lightning Flash: A modular mechanical thrombectomy system built for treatment of pulmonary embolism and venous thrombus
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Penumbra
Cerus Endovascular
HQ: United Kingdom
Website
- Description: Provider of interventional neuroradiology devices and delivery systems, including the e-clipse aneurysm occlusive device that addresses neurovascular aneurysm procedures currently attempted by surgical clipping, minimally invasive metal coils, and liquid embolics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerus Endovascular company profile →
Allon Therapeutics
HQ: Canada
Website
- Description: Provider of clinical-stage biopharmaceutical drug development for neurodegenerative diseases, with lead product Davunetide intranasal in Phase IIa clinical trials for Alzheimer's disease, schizophrenia cognitive impairment, and frontotemporal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allon Therapeutics company profile →
Mitokinin
HQ: United States
Website
- Description: Provider of biotechnology R&D focused on medicinal chemistry to generate kinetin analogs optimized for activating PINK1, with plans to develop these analogs or optimized variants to treat Parkinson's disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mitokinin company profile →
CuraSen Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for neurodegenerative diseases, developing orphan drugs including CST-103/CST-107, a combination therapy targeting cognitive symptoms and disease progression in Parkinson’s disease (Phase 2); CST-2032/CST-107 for Alzheimer’s disease with similar focus (Phase 2); and CST-3056, an alpha-1A adrenoceptor agonist in preclinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CuraSen Therapeutics company profile →
Eleusian Biosciences
HQ: Canada
Website
- Description: Provider of therapeutics in development for multiple pathological psychological diseases, based on psilocybin plus N-acetylcysteine (NAC) compounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eleusian Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Penumbra
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Penumbra
2.2 - Growth funds investing in similar companies to Penumbra
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Penumbra
4.2 - Public trading comparable groups for Penumbra
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →